Nat Commun:lncRNA调控免疫反应

2014-06-25 佚名 不详

近日,Mark Lindsay教授领导的一个研究小组在确定调节免疫反应的基因中取得了突破性进展。 免疫反应辨识和捍卫机体免受危险微生物的侵害。在正常情况下,一旦威胁已经过去了,免疫反应会关闭。然而,这种情况并不总是发生,结果会导致诸如哮喘,糖尿病和癌症以及自身免疫疾病,心血管疾病和呼吸系统等疾病。 出于这个原因,科学家们花了很多年试图理解控制免疫反应的机制。采用最新的DNA测序技术,来自Bat

近日,Mark Lindsay教授领导的一个研究小组在确定调节免疫反应的基因中取得了突破性进展。

免疫反应辨识和捍卫机体免受危险微生物的侵害。在正常情况下,一旦威胁已经过去了,免疫反应会关闭。然而,这种情况并不总是发生,结果会导致诸如哮喘,糖尿病和癌症以及自身免疫疾病,心血管疾病和呼吸系统等疾病。

出于这个原因,科学家们花了很多年试图理解控制免疫反应的机制。采用最新的DNA测序技术,来自Bath, Oxford, Imperial, Liverpool和Manchester大学的科研团队发现了一个基因家族即所谓的长链非编码RNA在控制免疫反应中起到一定作用。

Lindsay教授说:DNA测序和计算技术的进步允许我们识别调节免疫反应的新机制,我们的发现有可能提供一种新的方法来治疗多种疾病。

原始出处

IIott NE1, Heward JA2, Roux B3, Tsitsiou E4, Fenwick PS5, Lenzi L6, Goodhead I6, Hertz-Fowler C6, Heger A7, Hall N6, Donnelly LE5, Sims D7, Lindsay MA8.Long non-coding RNAs and enhancer RNAs regulate the lipopolysaccharide-induced inflammatory response in human monocytes.Nat Commun. 2014 Jun 9

版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (5)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=2086711, encodeId=9ca42086e1101, content=<a href='/topic/show?id=490750196b' target=_blank style='color:#2F92EE;'>#COMMUN#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=25, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5019, encryptionId=490750196b, topicName=COMMUN)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=7931272, createdName=liuli5079, createdTime=Sun May 24 00:16:00 CST 2015, time=2015-05-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1880135, encodeId=5db418801356f, content=<a href='/topic/show?id=3b2112532d8' target=_blank style='color:#2F92EE;'>#Nat#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=21, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=12532, encryptionId=3b2112532d8, topicName=Nat)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4c37265, createdName=zhaojie88, createdTime=Wed Apr 22 02:16:00 CST 2015, time=2015-04-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2005617, encodeId=9d8e200561e85, content=<a href='/topic/show?id=6ff1525e13' target=_blank style='color:#2F92EE;'>#CRN#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5257, encryptionId=6ff1525e13, topicName=CRN)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=35fc2500023, createdName=yanjie6253_56072842, createdTime=Sat Jul 26 15:16:00 CST 2014, time=2014-07-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1280124, encodeId=5b07128012405, content=<a href='/topic/show?id=2bbe289846f' target=_blank style='color:#2F92EE;'>#免疫反应#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=39, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=28984, encryptionId=2bbe289846f, topicName=免疫反应)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=827b160, createdName=cnxcy, createdTime=Fri Jun 27 00:16:00 CST 2014, time=2014-06-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1301848, encodeId=dc7c1301848ca, content=<a href='/topic/show?id=b469109e41d' target=_blank style='color:#2F92EE;'>#lncRNA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=39, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=10974, encryptionId=b469109e41d, topicName=lncRNA)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=2317301, createdName=xzw113, createdTime=Fri Jun 27 00:16:00 CST 2014, time=2014-06-27, status=1, ipAttribution=)]
    2015-05-24 liuli5079
  2. [GetPortalCommentsPageByObjectIdResponse(id=2086711, encodeId=9ca42086e1101, content=<a href='/topic/show?id=490750196b' target=_blank style='color:#2F92EE;'>#COMMUN#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=25, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5019, encryptionId=490750196b, topicName=COMMUN)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=7931272, createdName=liuli5079, createdTime=Sun May 24 00:16:00 CST 2015, time=2015-05-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1880135, encodeId=5db418801356f, content=<a href='/topic/show?id=3b2112532d8' target=_blank style='color:#2F92EE;'>#Nat#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=21, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=12532, encryptionId=3b2112532d8, topicName=Nat)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4c37265, createdName=zhaojie88, createdTime=Wed Apr 22 02:16:00 CST 2015, time=2015-04-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2005617, encodeId=9d8e200561e85, content=<a href='/topic/show?id=6ff1525e13' target=_blank style='color:#2F92EE;'>#CRN#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5257, encryptionId=6ff1525e13, topicName=CRN)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=35fc2500023, createdName=yanjie6253_56072842, createdTime=Sat Jul 26 15:16:00 CST 2014, time=2014-07-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1280124, encodeId=5b07128012405, content=<a href='/topic/show?id=2bbe289846f' target=_blank style='color:#2F92EE;'>#免疫反应#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=39, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=28984, encryptionId=2bbe289846f, topicName=免疫反应)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=827b160, createdName=cnxcy, createdTime=Fri Jun 27 00:16:00 CST 2014, time=2014-06-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1301848, encodeId=dc7c1301848ca, content=<a href='/topic/show?id=b469109e41d' target=_blank style='color:#2F92EE;'>#lncRNA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=39, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=10974, encryptionId=b469109e41d, topicName=lncRNA)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=2317301, createdName=xzw113, createdTime=Fri Jun 27 00:16:00 CST 2014, time=2014-06-27, status=1, ipAttribution=)]
    2015-04-22 zhaojie88
  3. [GetPortalCommentsPageByObjectIdResponse(id=2086711, encodeId=9ca42086e1101, content=<a href='/topic/show?id=490750196b' target=_blank style='color:#2F92EE;'>#COMMUN#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=25, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5019, encryptionId=490750196b, topicName=COMMUN)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=7931272, createdName=liuli5079, createdTime=Sun May 24 00:16:00 CST 2015, time=2015-05-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1880135, encodeId=5db418801356f, content=<a href='/topic/show?id=3b2112532d8' target=_blank style='color:#2F92EE;'>#Nat#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=21, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=12532, encryptionId=3b2112532d8, topicName=Nat)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4c37265, createdName=zhaojie88, createdTime=Wed Apr 22 02:16:00 CST 2015, time=2015-04-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2005617, encodeId=9d8e200561e85, content=<a href='/topic/show?id=6ff1525e13' target=_blank style='color:#2F92EE;'>#CRN#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5257, encryptionId=6ff1525e13, topicName=CRN)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=35fc2500023, createdName=yanjie6253_56072842, createdTime=Sat Jul 26 15:16:00 CST 2014, time=2014-07-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1280124, encodeId=5b07128012405, content=<a href='/topic/show?id=2bbe289846f' target=_blank style='color:#2F92EE;'>#免疫反应#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=39, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=28984, encryptionId=2bbe289846f, topicName=免疫反应)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=827b160, createdName=cnxcy, createdTime=Fri Jun 27 00:16:00 CST 2014, time=2014-06-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1301848, encodeId=dc7c1301848ca, content=<a href='/topic/show?id=b469109e41d' target=_blank style='color:#2F92EE;'>#lncRNA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=39, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=10974, encryptionId=b469109e41d, topicName=lncRNA)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=2317301, createdName=xzw113, createdTime=Fri Jun 27 00:16:00 CST 2014, time=2014-06-27, status=1, ipAttribution=)]
  4. [GetPortalCommentsPageByObjectIdResponse(id=2086711, encodeId=9ca42086e1101, content=<a href='/topic/show?id=490750196b' target=_blank style='color:#2F92EE;'>#COMMUN#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=25, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5019, encryptionId=490750196b, topicName=COMMUN)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=7931272, createdName=liuli5079, createdTime=Sun May 24 00:16:00 CST 2015, time=2015-05-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1880135, encodeId=5db418801356f, content=<a href='/topic/show?id=3b2112532d8' target=_blank style='color:#2F92EE;'>#Nat#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=21, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=12532, encryptionId=3b2112532d8, topicName=Nat)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4c37265, createdName=zhaojie88, createdTime=Wed Apr 22 02:16:00 CST 2015, time=2015-04-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2005617, encodeId=9d8e200561e85, content=<a href='/topic/show?id=6ff1525e13' target=_blank style='color:#2F92EE;'>#CRN#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5257, encryptionId=6ff1525e13, topicName=CRN)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=35fc2500023, createdName=yanjie6253_56072842, createdTime=Sat Jul 26 15:16:00 CST 2014, time=2014-07-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1280124, encodeId=5b07128012405, content=<a href='/topic/show?id=2bbe289846f' target=_blank style='color:#2F92EE;'>#免疫反应#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=39, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=28984, encryptionId=2bbe289846f, topicName=免疫反应)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=827b160, createdName=cnxcy, createdTime=Fri Jun 27 00:16:00 CST 2014, time=2014-06-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1301848, encodeId=dc7c1301848ca, content=<a href='/topic/show?id=b469109e41d' target=_blank style='color:#2F92EE;'>#lncRNA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=39, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=10974, encryptionId=b469109e41d, topicName=lncRNA)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=2317301, createdName=xzw113, createdTime=Fri Jun 27 00:16:00 CST 2014, time=2014-06-27, status=1, ipAttribution=)]
  5. [GetPortalCommentsPageByObjectIdResponse(id=2086711, encodeId=9ca42086e1101, content=<a href='/topic/show?id=490750196b' target=_blank style='color:#2F92EE;'>#COMMUN#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=25, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5019, encryptionId=490750196b, topicName=COMMUN)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=7931272, createdName=liuli5079, createdTime=Sun May 24 00:16:00 CST 2015, time=2015-05-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1880135, encodeId=5db418801356f, content=<a href='/topic/show?id=3b2112532d8' target=_blank style='color:#2F92EE;'>#Nat#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=21, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=12532, encryptionId=3b2112532d8, topicName=Nat)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4c37265, createdName=zhaojie88, createdTime=Wed Apr 22 02:16:00 CST 2015, time=2015-04-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2005617, encodeId=9d8e200561e85, content=<a href='/topic/show?id=6ff1525e13' target=_blank style='color:#2F92EE;'>#CRN#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5257, encryptionId=6ff1525e13, topicName=CRN)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=35fc2500023, createdName=yanjie6253_56072842, createdTime=Sat Jul 26 15:16:00 CST 2014, time=2014-07-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1280124, encodeId=5b07128012405, content=<a href='/topic/show?id=2bbe289846f' target=_blank style='color:#2F92EE;'>#免疫反应#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=39, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=28984, encryptionId=2bbe289846f, topicName=免疫反应)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=827b160, createdName=cnxcy, createdTime=Fri Jun 27 00:16:00 CST 2014, time=2014-06-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1301848, encodeId=dc7c1301848ca, content=<a href='/topic/show?id=b469109e41d' target=_blank style='color:#2F92EE;'>#lncRNA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=39, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=10974, encryptionId=b469109e41d, topicName=lncRNA)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=2317301, createdName=xzw113, createdTime=Fri Jun 27 00:16:00 CST 2014, time=2014-06-27, status=1, ipAttribution=)]
    2014-06-27 xzw113

相关资讯

基因疗法有望攻克地中海贫血症

两名地中海贫血症患者参加了蓝鸟生物公司(Bluebird Bio)针对该罕见血液病的基因治疗实验,在接受治疗的12天之内,他们能够停止输血治疗。 2010年,该疗法一个更早的版本就刊登在了《自然》(Nature)杂志上,当时这一疗法使一名地中海贫血患者有长达六年的时间不用接受输血治疗。但在接受完该疗法不能马上停止输血,而是要等到12个月之后。新的数据给人的希望是,蓝鸟公司的升级版疗法比之前

Lancet:RNAi基因治疗新药ALN-PCS明显降低患者胆固醇水平(临床I期研究)

胆固醇高者通常需要服用他汀类药物以降低心脏病风险,但此类药物副作用较明显。最新完成的临床试验显示,一种通过调控基因来降低胆固醇的药物同样有效,且无明显副作用。 由Alnylam 公司研发,在英国盖氏医院研究人员与美国同行一起,在英国新一期《柳叶刀》杂志上报告说,一种被称为“ALN-PCS”的新药,可通过干扰核糖核酸来抑制PCSK9 基因的表达,使身体清除有害胆固醇的能力恢复正常。 研究人员招募

我国启动艾滋病基因治疗研究

国家卫生计生委艾滋病防治科技重大专项“基于自体造血干/祖细胞遗传改造的艾滋病基因治疗”日前在武汉大学启动,探索艾滋病功能性治愈方法。 据悉,目前世界上尚无针对艾滋病的特效或根治性治疗方法。虽然鸡尾酒疗法在减轻患者痛苦、延长患者寿命等方面取得了一定的效果,但药物只能控制病毒复制,不能彻底清除病毒。基因治疗是取代疫苗或药物治疗的可行性方法之一,有望通过对感染个体嵌入一个或者多个基因抵抗艾滋病病毒。

Lancet:基因治疗无脉络膜症临床研究获进展(Phase 1/2)

无脉络膜症(choroideremia),又称全脉络膜血管萎缩、进行性脉络膜萎缩、进行性毯层脉络膜萎缩。由Mauthner于1872年首次报道,最初从眼底的表现观察到与原发性视网膜变性有所不同,认为是脉络膜的缺失。经过长期观察发现,脉络膜与色素上皮并不是先天性发育不良而是后天进行性消失,故又称为进行性RPE(视网膜上皮色素细胞,retinal pigment epitheliu

Lancet:基因治疗帕金森病任重道远

3月29日的The Lancet杂志上发表了一篇来自加拿大太平洋帕金森研究中心Stoessl教授的评论,文章主要围绕Lancet杂志1月份发表的帕金森病三重基因疗法展开,并对帕金森治疗的方法进行了评价,具体内容如下:帕金森病是第二常见的神经系统退行性病变。截至2010年,欧洲几乎每年在帕金森病上都要投入近140亿资金。其对帕金森病患者及其家庭的生活质量的影响更是无法评估。帕金森病的主要病理改变

Nature:癌症治疗迎来新拐点

癌细胞通过不同寻常的代谢途径获取维持不断增殖所必需的分子材料和能量,许多有望治愈癌症的药物就是在利用它的这种“饥饿”特性。近日,在加州圣地亚哥市举行的美国癌症研究协会年会上,一种基于基因的药物早期研究结果被公布于众——该药物有望成功治愈癌症。德国维尔茨堡大学癌症研究者Almut Schulze说:“癌症治疗迎来了一个转折点。”某种意义上说,这一新发现把癌症研究带回了原点。在20世纪绝大部分时间里,